Human Insulin Market

Report Overview

The global human insulin market was pegged at US$ 42.5 billion in 2021 and is expected to witness a CAGR of 7.8% during the forecast period.

Market Fundamentals 

Insulin is a hormone that controls the body's blood sugar levels. Diabetes is a chronic medical condition characterized by elevated blood glucose or sugar level. Uncontrolled diabetes causes hyperglycemia, or high blood sugar, which can cause serious damage to many of the body's systems, particularly the nerves and blood vessels, over time. Diabetes is currently classified into two types. Type I diabetes occurs when the pancreatic beta cells stop producing insulin, and type II occurs when the body's cells lose sensitivity to the insulin produced.

Human insulin (HI) is a type of synthetic insulin that is manufactured in laboratories for pharmaceutical purposes. It is bioengineered by growing insulin proteins within e-coli bacteria (Escherichia coli, a gram-negative bacteria) cells to mimic the properties of human insulin. There are three types of Human Insulin drugs: rapid-acting, long-acting, and premixed HI. They are administered subcutaneously as a solution or suspension and aid in the uptake of glucose from the blood into internal organs such as fat cells, skeletal muscles, and the liver. They also reduce hepatic glucose production, proteolysis, and lipolysis while increasing protein synthesis.

[4574543]

Market Dynamics

One of the key factors driving the market growth is the rising prevalence of obesity and diabetes around the world. Because of sedentary lifestyles, an aging population, and poor dietary habits, an increasing number of people are suffering from chronic lifestyle diseases, increasing the demand for insulin therapeutics. Furthermore, the increasing demand for biosimilar drugs, owing to their high efficiency and cost-effectiveness, is driving the market growth. Various technological advancements, such as the development of pen devices and safety pen needles for administering HI in the body, are also contributing to market growth.

Market Ecosystem

The global human insulin market has been analyzed from five perspectives: Drugs, Distribution Channels, Application, and Region. 

Human Insulin Market by Drugs

[98767544]

Based on drugs, the human insulin market has been segmented into biosimilars and biologics. Biosimilars are sub-segmented into long acting, rapid acting, and pre-mixed biosimilar whereas Biologics segment is also categorized into intermediate-acting, short-acting, and premixed biologics. The biosimilar segment is expected to grow at the fastest rate during the forecasted period. The driving factors include its slow action and adaptability to the human body, rising diabetic population worldwide, rising R&D for drug discovery and development, the rising proportion of aging population in developed countries, rising market accessibility of generic human insulin products globally, and rising government initiatives to support the development and commercialization of effective biosimilars.

Human Insulin Market by Distribution Channels

Based on distribution channels, the human insulin market has been segmented into retail, hospital, and online pharmacy. During the forecast period, retail pharmacy is expected to generate the most revenue in the insulin industry. The increased availability of insulin in the retail channel is expected to be the primary driving factor for the segment. However, the recent trend of online pharmacy adoption for insulin is expected to boost the online pharmacy market segment. This is primarily due to the increasing discounts provided by the online pharmacy in comparison to the more expensive insulin available on the market.

Human Insulin Market by Applications

Based on applications, the human insulin market has been segmented into type I diabetes, and type II diabetes. Type I diabetes market is dominated the market during the forecast period due to growing rate of diagnosis of type I diabetes. Insulin-dependent diabetes is another name for type I diabetes, in that case, pancreatic cells produce little or no insulin, necessitating artificial supplementation.

Human Insulin Market by Region

Based on the region, the global human insulin market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America, particularly the United States, dominates the global human insulin market, owing to the region's high prevalence of diabetes due to its sedentary lifestyle. The cost factor is a major concern in the United States, where the country accounts for nearly half of insulin revenue for manufacturers. Major players' primary strategies for strengthening their positions in the global market are geographic expansion and product development. Furthermore, A significant number of market players also used strategies such as partnerships, agreements, collaborations, awareness campaigns, and research funding & grants to strengthen their product portfolios and grow their dispersal networks in the global human insulin market.

Competitive Landscape

Some of the key players in the global human insulin market are 

• Novo Nordisk A/S
• Sanofi S.A
• Eli Lilly and Company
• Biocon Ltd
• GlaxoSmithCline
• julphar
• SemBioSys
• Wockhardt Limited
• Astra Zeneca PLC
• Tonghua Dongbao Pharmaceutical
• Pfizer Inc
• Merck & Co

Strategic Developments 

• In February 2022, Biocon has formed a joint venture with Viatris (formerly Mylan) to develop and commercialize a wide range of insulin and biosimilar products, including human insulin, as part, insulin glargine, bevacizumab, trastuzumab, and in-licensed products adalimumab, pegfilgrastim, and etanercept.
• In July 2021, Walmart announced a collaboration agreement with Novo Nordisk to launch the first-ever private brand analog insulin, which will retail for up to 75% less than the cash price of branded insulin products.
• In February 2021, As the first biosimilar insulin company, Biocon Biologics collaborated with the International Diabetes Federation (IDF) to promote and support the IDF's critical mission initiative. The collaboration kicks off the centennial commemoration of the invention of insulin and advances Biocon Biologics' goal of providing affordable insulin to people with diabetes all over the world.
• In September 2019, Sanofi and Abbott are collaborating to integrate glucose sensing and insulin delivery technology, which will help people with diabetes manage their disease more easily. The two companies will take a novel approach to connected care by developing solutions that combine the ground-breaking FreeStyle Libre technology with insulin dosing data for future smartpens, insulin titration apps, and other connected care devices.

Frequently Asked Questions About This Report